THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.
THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.
复制标题
DOI：
10.18632/oncotarget.28099
复制
发表时间：
2021-10-26
期刊：
影响因子：
--
通讯作者：
Zaret KS
中科院分区：
文献类型：
--
作者：
Gimotty PA;Till JE;Udgata S;Takenaka N;Yee SS;LaRiviere MJ;O'Hara MH;Reiss KA;O'Dwyer P;Katona BW;Herman D;Carpenter EL;Zaret KS
新诊断的转移性胰腺导管腺癌患者的生存率通常较差，且进展率存在差异。可以预测进展和/或生存的生物标志物将有助于患者和提供者做出护理决定。在之前的一项回顾性研究中，我们发现循环血小板反应蛋白-2 (THBS2) 与 CA19-9 结合可以更好地区分 PDAC 患者与健康对照。在此，我们评估了 68 名患者在诊断转移性 PDAC 时的 THBS2 水平（之前不知道其与预后相关）是否与预后相关。具体来说，我们探讨了 THBS2 水平单独或与 CA19-9 组合与 90 天进展和/或生存至 180 天的关系。结果表明，在诊断转移性 PDAC 时，仅升高 THBS2 水平就可以识别死亡时间较短的患者，从而在计划治疗时帮助患者和提供者。
Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and providers as they make care decisions. In a previous retrospective study, we discovered that circulating thrombospondin-2 (THBS2) could, in combination with CA19-9, better distinguish patients with PDAC versus healthy controls. Here we evaluated whether THBS2 levels, previously not known to be prognostic, were associated with outcome in 68 patients at time of diagnosis of metastatic PDAC. Specifically, we interrogated the association of THBS2 level, alone or in combination with CA19-9, with progression by 90 days and/or survival to 180 days. The results indicate that elevated THBS2 levels alone, at the time of a metastatic PDAC diagnosis, can identify patients with a shorter time to death and thus help patients and providers when planning treatment.